These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 22939905)

  • 1. KIR2DS2 and KIR2DS4 promoter hypomethylation patterns in patients undergoing hematopoietic cell transplantation (HCT).
    Gallez-Hawkins GM; Li X; Franck AE; Gendzekhadze K; Nakamura R; Forman SJ; Senitzer D; Zaia JA
    Hum Immunol; 2012 Nov; 73(11):1109-15. PubMed ID: 22939905
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of activating KIR2DS2 and KIR2DS4 genes after hematopoietic cell transplantation: relevance to cytomegalovirus infection.
    Gallez-Hawkins GM; Franck AE; Li X; Thao L; Oki A; Gendzekhadze K; Dagis A; Palmer J; Nakamura R; Forman SJ; Senitzer D; Zaia JA
    Biol Blood Marrow Transplant; 2011 Nov; 17(11):1662-72. PubMed ID: 21596150
    [TBL] [Abstract][Full Text] [Related]  

  • 3. KIR2DS4 and Its Variant KIR1D Are Associated with Acute Graft-versus-Host Disease, Cytomegalovirus, and Overall Survival after Sibling-Related HLA-Matched Transplantation in Patients with Donors with KIR Gene Haplotype A.
    Wu X; Yao Y; Bao X; Zhou H; Tang X; Han Y; Ma X; Liu Y; Chen J; Zhou H; Jing S; Gu B; Xu Y; Sun A; He J; Wu D
    Biol Blood Marrow Transplant; 2016 Feb; 22(2):220-225. PubMed ID: 26476204
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dynamic mRNA expression of donor-derived activating KIR genes and their significant effects on clinical outcome after haematopoietic stem cell transplantation.
    Li Y; Wang T; Hu X; Zhang H; Bao X; Wu D; He J
    Clin Exp Immunol; 2021 Sep; 205(3):417-428. PubMed ID: 34085290
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Donor-Recipient Matching for KIR Genotypes Reduces Chronic GVHD and Missing Inhibitory KIR Ligands Protect against Relapse after Myeloablative, HLA Matched Hematopoietic Cell Transplantation.
    Faridi RM; Kemp TJ; Dharmani-Khan P; Lewis V; Tripathi G; Rajalingam R; Daly A; Berka N; Storek J; Masood Khan F
    PLoS One; 2016; 11(6):e0158242. PubMed ID: 27341514
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of activating killer immunoglobulin-like receptor genotype on outcome of unrelated donor-hematopoietic cell transplantation.
    Giebel S; Nowak I; Wojnar J; Markiewicz M; Dziaczkowska J; Wylezol I; Krawczyk-Kulis M; Bloch R; Kusnierczyk P; Holowiecki J
    Transplant Proc; 2006; 38(1):287-91. PubMed ID: 16504727
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The impact of KIR2DS4 gene on clinical outcome after hematopoietic stem cell transplantation.
    Burek Kamenaric M; Stingl Jankovic K; Grubic Z; Serventi Seiwerth R; Maskalan M; Nemet D; Mikulic M; Zunec R
    Hum Immunol; 2017 Feb; 78(2):95-102. PubMed ID: 27998801
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Distribution of killer cell immunoglobulin-like receptor genes and 2DS4 alleles in the Chinese Han population.
    Bao X; Hou L; Sun A; Qiu Q; Yuan X; Chen M; Chen Z; He J
    Hum Immunol; 2010 Mar; 71(3):289-92. PubMed ID: 20034528
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Influence of donor activating or inhibitory KIR on prognosis of unmanipulated allogeneic hematopoietic stem cell transplantation].
    Liang ZY; Ren HY; Cen XN; Qiu ZX; Wang LH; Ou JP; Li Y; Wang MJ; Wang WS; Xu WL; Dong YJ; Yin Y; Sun YH
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Feb; 21(1):155-60. PubMed ID: 23484711
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Study of KIR gene expression at the mRNA level in specific donor-derived NK cells after allogeneic HSCT.
    Li Y; Wang T; Hu X; Zhang H; Chen L; Bao X; He J
    Immunogenetics; 2020 Apr; 72(3):135-141. PubMed ID: 31900503
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of single and combined activating killer immunoglobulin-like receptor genotypes on cytomegalovirus infection and immunity after hematopoietic cell transplantation.
    Zaia JA; Sun JY; Gallez-Hawkins GM; Thao L; Oki A; Lacey SF; Dagis A; Palmer J; Diamond DJ; Forman SJ; Senitzer D
    Biol Blood Marrow Transplant; 2009 Mar; 15(3):315-25. PubMed ID: 19203722
    [TBL] [Abstract][Full Text] [Related]  

  • 12. KIR2DS4 and Its Variant KIR1D in KIR-AA Genotype Donors Showed Differential Survival Impact in Patients with Lymphoid Disease after HLA-Matched Unrelated Hematopoietic Stem Cell Transplantation.
    Gowdavally S; Tsamadou C; Platzbecker U; Sala E; Valerius T; Klein S; Kröger N; Wulf G; Einsele H; Thurner L; Schaefer-Eckart K; Freitag S; Casper J; Dürholt M; Kaufmann M; Hertenstein B; Ringhoffer M; Schmeller S; Neuchel C; Rode I; Amann EM; Richter A; Schrezenmeier H; Mytilineos J; Fuerst D
    Transplant Cell Ther; 2023 Jul; 29(7):457.e1-457.e10. PubMed ID: 37150297
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of Donor Activating KIR-HLA Ligand-Mediated NK Cell Education Status in Control of Malignancy in Hematopoietic Cell Transplant Recipients.
    Nowak J; Kościńska K; Mika-Witkowska R; Rogatko-Koroś M; Mizia S; Jaskuła E; Polak M; Mordak-Domagała M; Lange J; Gronkowska A; Jędrzejczak WW; Kyrcz-Krzemień S; Markiewicz M; Dzierżak-Mietła M; Tomaszewska A; Nasiłowska-Adamska B; Szczepiński A; Hałaburda K; Hellmann A; Czyż A; Gil L; Komarnicki M; Wachowiak J; Barańska M; Kowalczyk J; Drabko K; Goździk J; Wysoczańska B; Bogunia-Kubik K; Graczyk-Pol E; Witkowska A; Marosz-Rudnicka A; Nestorowicz K; Dziopa J; Szlendak U; Warzocha K; Lange A;
    Biol Blood Marrow Transplant; 2015 May; 21(5):829-39. PubMed ID: 25617806
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HLA-Cw polypmorphism and killer cell immunoglobulin-like receptor (KIR) gene analysis in Korean colorectal cancer patients.
    Kim HJ; Choi HB; Jang JP; Baek IC; Choi EJ; Park M; Kim TG; Oh ST
    Int J Surg; 2014; 12(8):815-20. PubMed ID: 24998207
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Donor Killer Immunoglobulin Receptor Gene Content and Ligand Matching and Outcomes of Pediatric Patients with Juvenile Myelomonocytic Leukemia Following Unrelated Donor Transplantation.
    Rangarajan HG; Pereira MSF; Brazauskas R; St Martin A; Kussman A; Elmas E; Verneris MR; Gadalla SM; Marsh SGE; Paczesny S; Spellman SR; Lee SJ; Lee DA
    Transplant Cell Ther; 2021 Nov; 27(11):926.e1-926.e10. PubMed ID: 34407489
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evidence for epigenetic maintenance of Ly49a monoallelic gene expression.
    Rouhi A; Gagnier L; Takei F; Mager DL
    J Immunol; 2006 Mar; 176(5):2991-9. PubMed ID: 16493057
    [TBL] [Abstract][Full Text] [Related]  

  • 17. NK cells with KIR2DS2 immunogenotype have a functional activation advantage to efficiently kill glioblastoma and prolong animal survival.
    Gras Navarro A; Kmiecik J; Leiss L; Zelkowski M; Engelsen A; Bruserud Ø; Zimmer J; Enger PØ; Chekenya M
    J Immunol; 2014 Dec; 193(12):6192-206. PubMed ID: 25381437
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The impact of donor full-length KIR2DS4 in the development of acute and chronic GVHD after unrelated allogeneic HSCT.
    An K; Li B; Luo C; Wang J; Luo C; Chen J
    Pediatr Transplant; 2020 Sep; 24(6):e13728. PubMed ID: 32594584
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genome-wide profiling of DNA methylation reveals a class of normally methylated CpG island promoters.
    Shen L; Kondo Y; Guo Y; Zhang J; Zhang L; Ahmed S; Shu J; Chen X; Waterland RA; Issa JP
    PLoS Genet; 2007 Oct; 3(10):2023-36. PubMed ID: 17967063
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Peptide: MHC-based DNA vaccination strategy to activate natural killer cells by targeting killer cell immunoglobulin-like receptors.
    Rettman P; Blunt MD; Fulton RJ; Vallejo AF; Bastidas-Legarda LY; España-Serrano L; Polak ME; Al-Shamkhani A; Retiere C; Khakoo SI
    J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34016721
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.